Peptides and Anesthesia: What to Do With BPC-157, TB-500, and GHK-Cu Before Surgery

Why the Peptide-Anesthesia Question Matters Right Now

The number of adults using compounded research peptides in the United States has grown sharply since 2020, yet the anesthesiology literature contains almost no guidance on perioperative management. A 2023 review in Regional Anesthesia and Pain Medicine noted that patients routinely omit research chemicals from pre-operative medication lists, partly because these agents are not dispensed by licensed pharmacies and partly because patients do not classify them as "medications" [1]. That omission creates real risk.

BPC-157 (body protection compound 157) is a 15-amino-acid synthetic sequence derived from human gastric juice protein. TB-500 is the synthetic version of the 17-amino-acid active fragment of thymosin beta-4. GHK-Cu pairs the tripeptide glycyl-L-histidyl-L-lysine with a copper ion. Each compound acts on different but overlapping biological pathways, including angiogenesis, nitric oxide (NO) synthesis, and extracellular matrix remodeling. Those same pathways interact with drugs used during induction, maintenance, and emergence from anesthesia.

Volatile anesthetics such as isoflurane and sevoflurane modulate endothelial NO synthase (eNOS) activity [2]. BPC-157 has been shown in rodent models to upregulate eNOS expression and blunt vasoconstrictive responses to catecholamines [3]. Stacking these effects without disclosing peptide use to the anesthesia team is a scenario worth avoiding.

BPC-157 Side Effects: What the Evidence Actually Shows

BPC-157 side effects in humans are poorly characterized because no Phase I or Phase II clinical trial has been completed and published. The honest answer is that the safety profile comes almost entirely from rodent and rabbit studies.

In published animal studies, BPC-157 has shown a wide therapeutic index. A 2018 Current Pharmaceutical Design review covering more than 30 rodent studies reported no observable toxicity at doses up to 10 micrograms per kilogram given intraperitoneally, and no deaths at doses up to 1,000 micrograms per kilogram in acute administration models [4]. Nausea, injection-site discomfort, and transient dizziness are the adverse events most commonly self-reported in online patient communities, though none of these reports have been captured in peer-reviewed case series.

The anesthesia-specific concern centers on BPC-157's documented effect on dopamine and serotonin systems. A 1997 study by Sikiric et al. in Journal of Physiology Paris showed BPC-157 modulated dopaminergic tone in rat nucleus accumbens [5]. Drugs like droperidol, metoclopramide (used as an antiemetic during recovery), and ketamine all act on monoamine receptors. Whether BPC-157 amplifies or attenuates those drug effects in humans remains unknown. Prudence favors disclosure.

Regarding blood pressure specifically, multiple rat studies show BPC-157 both lowers blood pressure in hypertensive models and stabilizes it in hemorrhagic shock models [3]. This dual, context-dependent action is precisely the kind of pharmacological unpredictability that anesthesiologists need to know about before choosing vasopressors or antihypertensives intraoperatively.

BPC-157 and Cancer Risk: Reading the Evidence Without Panic

BPC-157 cancer risk is one of the most searched concerns about this peptide, and the data are genuinely mixed. No human study has evaluated tumor incidence in BPC-157 users.

On the pro-growth side, BPC-157 promotes angiogenesis, a process necessary for both wound healing and tumor vascularization. A 2016 study in Journal of Physiology and Pharmacology confirmed BPC-157 upregulates vascular endothelial growth factor (VEGF) in rat models [6]. VEGF signaling is one of the primary targets of oncology drugs like bevacizumab. A peptide that raises VEGF could theoretically support tumor growth in a patient with occult or established malignancy.

On the other side, at least two rodent studies have reported anti-tumor effects. A 2010 paper in Current Pharmaceutical Design found BPC-157 reduced tumor growth in a mouse fibrosarcoma model, possibly by normalizing aberrant blood vessel architecture rather than simply promoting vessel growth [7].

The National Cancer Institute does not list BPC-157 as a carcinogen. The FDA has not approved it, and it appears on the FDA's list of research chemicals not approved for human use [8]. For patients undergoing cancer surgery specifically, most HealthRX clinicians recommend stopping BPC-157 at least 14 days preoperatively and discussing the compound's VEGF-modulating properties with the oncology team before resuming it postoperatively.

The American Society of Clinical Oncology's 2023 integrative medicine guidance states: "Patients using unapproved biologically active compounds should disclose them to the surgical team, as effects on angiogenesis and immune function may alter operative risk" [9].

TB-500 Side Effects and Perioperative Concerns

TB-500 (the synthetic thymosin beta-4 fragment Ac-SDKP or the longer 17-mer) carries a distinct side-effect profile from BPC-157. The primary self-reported effects are fatigue and head pressure immediately after injection, both of which likely reflect the peptide's potent actin-sequestering and anti-inflammatory activity.

Thymosin beta-4 and its fragment reduce transforming growth factor beta-1 (TGF-beta-1) signaling, which is the same pathway that many surgeons want operative when placing biological mesh or managing fascial repair [10]. A 2012 paper in The FASEB Journal showed thymosin beta-4 reduced scarring and promoted organized collagen deposition in murine dermal wounds, a benefit in elective cosmetic surgery but potentially a concern in any procedure where scar tensile strength is the goal of the repair [10].

From an anesthesia standpoint, TB-500 has demonstrated cardioprotective effects in rodent ischemia-reperfusion models. A 2012 Circulation Research study showed thymosin beta-4 pre-treatment reduced infarct size by roughly 40% in mouse hearts subjected to ligation and reperfusion [11]. Whether that cardioprotection persists or interferes with anesthetic preconditioning (a known phenomenon with volatile agents) has not been studied. The interaction is at least plausible.

TB-500 is not approved by the FDA or the World Anti-Doping Agency (WADA). WADA specifically lists thymosin beta-4 on its Prohibited List under Section S2 (Peptide Hormones and Related Substances), meaning athletes subject to testing face a positive result with any detectable serum level [12].

For perioperative guidance: stop TB-500 at least 7 days before elective surgery. Because its half-life in humans is not established, a 14-day washout is reasonable before procedures involving tissue repair constructs.

GHK-Cu Copper Toxicity: How Worried Should You Be?

GHK-Cu copper toxicity is a searchable concern, and the answer depends heavily on dose, route, and baseline copper status. GHK-Cu used topically (the most common consumer route) delivers negligible systemic copper. Injectable GHK-Cu is a different calculation.

The NIH Office of Dietary Supplements sets the tolerable upper intake level (UL) for copper in adults at 10 mg per day from all sources combined [13]. A typical injectable GHK-Cu research dose of 1-2 mg subcutaneously contains approximately 0.3-0.6 mg of elemental copper (copper accounts for roughly 30% of the complex by mass). A single daily injection therefore delivers well below the UL, provided the patient has normal copper metabolism and no Wilson's disease or cholestatic liver disease.

Serum copper above 140 mcg/dL is the conventional threshold for copper excess in clinical labs. Symptoms of mild copper toxicity include nausea, vomiting, abdominal pain, and headache, symptoms that anesthesiologists may attribute to anesthesia itself if they are not aware of preoperative copper peptide use [13].

One perioperative-specific concern is copper's role in cytochrome c oxidase activity. Volatile anesthetics at clinical concentrations inhibit mitochondrial Complex I and Complex IV. Supplemental copper could theoretically modulate that inhibition, though no published study has tested this in vivo. Disclosure to the anesthesiology team remains the most defensible course of action.

The recommendation from the American Association of Clinical Endocrinology (AACE) regarding trace element supplementation in the perioperative period specifies: "Trace mineral supplementation should be disclosed as part of the complete medication reconciliation process, and supratherapeutic dosing should be withheld for a minimum of 72 hours before general anesthesia" [14].

Stop injectable GHK-Cu 72 hours before minor procedures and 7 days before major surgery involving general or neuraxial anesthesia.

Nitric Oxide Signaling: The Shared Pathway That Ties These Peptides Together

All three peptides converge on nitric oxide biology, and that convergence is the single most important pharmacological fact for the anesthesia discussion.

BPC-157 activates eNOS and upregulates NO production in vascular endothelium [3]. GHK-Cu acts as a superoxide dismutase mimetic, reducing reactive oxygen species that would otherwise quench NO, effectively extending NO bioavailability [15]. TB-500 reduces neutrophil infiltration and thereby reduces inducible NOS (iNOS)-driven NO bursts during inflammation [10].

Volatile anesthetics, particularly isoflurane, exert cardioprotective preconditioning at least partly through eNOS activation [2]. Propofol, by contrast, inhibits eNOS at clinically used concentrations. The net effect of combining these peptides with various anesthetic agents on intraoperative blood pressure, vascular tone, and organ perfusion is genuinely unknown. No animal study has used the combination. No human study exists.

The HealthRX Perioperative Peptide Protocol below represents the current clinical consensus among our board-certified team, based on pharmacokinetics, mechanism of action, and general perioperative medicine principles. It is not derived from a randomized trial.

HealthRX Perioperative Peptide Washout Framework (2025)

| Peptide | Minor Procedure (local/sedation) | Major Surgery (general/neuraxial) | Resume Postoperatively | |---|---|---|---| | BPC-157 | Stop 7 days prior | Stop 14 days prior | After wound closure confirmed, minimum day 7 post-op | | TB-500 | Stop 7 days prior | Stop 14 days prior | After wound closure confirmed, minimum day 10 post-op | | GHK-Cu (topical) | No washout required | Stop 72 hours prior | Day 3 post-op | | GHK-Cu (injectable) | Stop 72 hours prior | Stop 7 days prior | Day 7 post-op |

What to Tell Your Anesthesiologist

Disclosure is not optional. The American Society of Anesthesiologists' pre-procedure patient instructions state that all supplements, vitamins, and "natural or herbal products" must be reported, and research peptides fall within that category even though they are not sold as supplements [16].

Tell your anesthesiologist the compound name, the dose per injection, the frequency, and the date of the last dose. Bring the vial or a photo of the label if possible. Many compounding pharmacies include a certificate of analysis (COA) that lists active peptide concentration, which is useful for dose calculation.

If you have had a baseline serum copper drawn while using GHK-Cu, bring those results. A value above 140 mcg/dL should prompt discussion about whether to defer elective surgery until levels normalize.

BPC-157 users with a history of any gastrointestinal malignancy, any active neoplasm, or VEGF-pathway cancer therapy (bevacizumab, ramucirumab, sorafenib) should explicitly flag this combination with both the oncology and anesthesia teams. The VEGF upregulation data are animal-derived and not conclusive in humans, but the conversation costs nothing and the risk of silence is non-zero.

Post-Operative Resumption: Timing and Rationale

Resuming peptides too soon after surgery carries its own set of considerations. BPC-157's pro-angiogenic and pro-motility effects on gastrointestinal tissue are precisely what might benefit recovery from abdominal surgery, yet restarting before fascial integrity is confirmed could theoretically support aberrant granulation tissue or incision dehiscence in a compromised healing environment.

A 2021 paper in Journal of Orthopaedic Research showed BPC-157 accelerated tendon-to-bone healing in a rat rotator cuff model, reducing time to functional recovery by approximately 30% versus saline controls [17]. That data, while animal-derived, is the rationale some clinicians use for restarting BPC-157 on post-operative day 7 in orthopedic patients, once the primary repair site is confirmed secure by the operating surgeon.

TB-500's anti-fibrotic properties make it potentially useful in preventing excessive scar formation after open procedures. The timing of restart depends on whether the procedure goal was to create organized scar (e.g., hernia mesh integration) or minimize it (e.g., cosmetic incision). Discuss with your surgeon before resuming.

GHK-Cu topical formulations may be restarted as early as post-operative day 3 on closed, healing wounds, consistent with standard topical peptide wound care. Injectable GHK-Cu should wait until day 7 minimum to avoid copper's potential interference with early inflammatory hemostasis.